World Conference on

Access to Medical Products Achieving the SDGs 2030

9-11 October 2018 New Delhi, IndiaProgramme Booklet

11

AcknowledgementsAccess to medicines is a critical factor for success of the 2030 Sustainable Development Agenda (SDG Agenda) that aims to ensure healthy lives and promote well- being of all people of all ages. The main objective of the Conference is to take forward the recommendations from the 1st World Conference 2017 and build on the work done for access to medical products in the context of SDGs (including trade agreements) in line with GPW 13 of WHO.

The World Health Organization would like to thank the following for their support and contribution to the ‘2nd World Conference on Access to Medical Products-Achieving the SDGs 2030’:

• Ministry of Health and Family Welfare, Government of India• World Health Organization• Indian Council of Medical Research • Translational Health Science and Technology • Biotechnology Industry Research Assistance Council• Biotech Consortium India Limited• Research & Innovation Systems in Developing Countries • Ministry of Culture, Government of India

Conference on Web

QR Code to Download the Mobile App

22

Working Group Members for Conference:• Mr Sudhir Kumar, Joint Secretary, Ministry of Health and Family Welfare, Government

of India - Chairman (Working Group)• Dr Manisha Shridhar, Regional Advisor, Intellectual Property Rights and Trade and

Health, WHO SEARO• Dr Madhur Gupta, Technical Officer-Pharmaceuticals, WHO Country Office for

India• Dr Sachin Mittal, Director, Ministry of Health and Family Welfare, Government of

India• Mr RG Singh, Under Secretary, Ministry of Health and Family Welfare, Government

of India• Dr Eswara Reddy, Drugs Controller General of India, CDSCO, Government of India

Conference Secretariat• Dr Manisha Shridhar, Regional Advisor, Intellectual Property Rights and Trade and

Health, WHO SEARO• Dr Madhur Gupta, Technical Officer-Pharmaceuticals, WHO Country Office for

India• Dr Purnima Sharma, CEO, Biotech Consortium India Limited• Ms Preeti Kharb, Consultant, WHO Country Office for India• Mr Santhana Krishnan V.S, Drug Regulation Division, Ministry of Health & Family

Welfare, Government of India• Dr Sanchita Chaudhary, Assistant General Manger, Biotech Consortium India

Limited• Ms Garima Singh, Consultant, Translational Health Science and Technology

Institute• Ms Kanika Dasan, Consultant, WHO SEARO

Overall Leadership, Guidance and Inputs• Ms Preeti Sudan, Secretary, Ministry of Health and Family Welfare, Government of

India• Dr RK Vats, Additional Secretary, Ministry of Health and Family Welfare, Government

of India• Dr VK Paul, Member, NITI Aayog, Government of India• Dr Balram Bhargava, Secretary, Department of Health Research, Ministry of Health

and Family Welfare, Government of India• Dr Renu Swarup, Secretary, Department of Biotechnology, Ministry of Science and

Technology, Government of India• Mr Ramesh Abhishek, Secretary, Department Of Industrial Policy & Promotion,

Ministry of Commerce and Industry, Government of India• Dr Arun Panda, Secretary, Ministry of Micro Small and Medium Enterprises,

Government of India

World Health Organization: • Dr Mariângela Batista Galvão Simão, Assistant Director-General for Drug Access,

Vaccines and Pharmaceuticals, WHO Headquarters, Geneva• Dr Henk Bekedam, WHO Representative, WHO Country Office for India• Ms Payden, Deputy WHO Representtaive, WHO Country Office for India• Dr Hilde Renne Susanne De Graeve, Team Leader, Health Systems, WHO Country

Office for India

33

• Ms Phyllida Travis, Director Health Systems Development, WHO SEARO• Dr Sue Hill, Director, Essential Medicines and Health Products, WHO Headquarters,

Geneva

Grateful for overall Support:

Ministry of Health and Family Welfare:• Honourable Mr JP Nadda, Union Minister, Ministry of Health and Family Welfare,

Government of India• Honorable Mr Ashwini Kumar Chaubey, Minister of State, Health & Family Welfare,

Government of India• Honorable Ms Anupriya Patel, Minister of State, Health & Family Welfare,

Government of India

Ministry of Science and Technology• Honorable Dr Harsh Vardhan, Union Minister, Ministry of Science and Technology,

Government of India

World Health Organization: • Dr Tedros Adhanom Ghebreyesus, Director General, World Health Organization • Dr Soumya Swaminathan Deputy Director General, WHO Headquarters, Geneva• Dr Poonam Khetrapal Singh, Regional Director, WHO South East Asia Region

44

Conference objectiveThe main objective of the 2nd World Conference 2018 is to take forward the recommendations from the 1st World Conference 2017 and build on the work done for access to medical products in the context of SDGs (including trade agreements) in line with GPW 13 of WHO.

Specific objectives1. Take forward recommendations of the 1st World Conference 2017 at national

and international levels2. Promote enabling ecosystem in the context of 13th GPW for access to medical

products 3. Foster new approaches in innovation landscape for medical products and health

technologies for accelerating research and innovation 4. Identify knowledge, information and policy options on the interface of international

trade and health to achieve SDG 2030 goals.

BackgroundWHO embarked on 13th Global Programme of Work1 (GPW13) for strategic direction in Sustainable Development Agenda 2030 (SDG) for health which is vital for the future of our world. The GPW13 states people continue to be susceptible to communicable diseases while the burden of non-communicable diseases is increasing. It is clear that reliable access to effective, safe, quality-assured and affordable medical products (medicines, vaccines, diagnostics, devices) is key to making progress towards Universal Health Coverage (UHC) and the SDGs. The WHO Constitution affirms the health of all people is fundamental to the attainment of peace and security and is dependent on the fullest cooperation of individual and States. GPW 13 is structured around the “triple billion” goal for three interconnected strategic priorities:

• Healthy Lives – 1 billion more people living healthier lives• Universal health coverage – 1 billion more people with universal health coverage• Health emergencies – 1 billion more people made safer (making us all safer)

The contribution of India for access to medical products worldwide is well recognized. India is a major manufacturer of medical products and generics. In vaccine manufacturing regulation rebenchmarking by a team of international experts convened by WHO in 2017 reaffirmed that the Indian National Regulatory Authority (NRA) is well equipped to produce and monitor safe, effective and quality vaccines. WHO prequalification of Indian manufacturers, facilitates supply of vaccines through the international procurement system, a major breakthrough for vaccine supplies to low- and middle-income countries. India is engaging in scientific progress and R&D for development of affordable products with supportive technology platforms, network of clinical sites and testing facilities and health technology innovation for meeting critical health needs.

In several recent WHA resolutions it has been recognized that health systems need to promote access to medical products (medicines, vaccines, diagnostics, devices) to ensure universal access to health care, rational use of medical products and the sustainability of health

1 Thirteenth General Programme of Work 2019−2023; http://www.who.int/about/what-we-do/gpw-thirteen-consultation/en/

55

systems2. Further, in 2016, the report of the UN Secretary-General’s High-Level Panel on Access to Health Technologies targeted incoherencies between trade and public health objectives. At this year’s World Health Assembly (WHA2018), the WHO Secretariat was tasked with developing a roadmap on access to medicines and medical products3, in time for the next Executive Board. Investment in research for new products, especially for health conditions prevalent in low- and middle-income countries, is essential. At the same time, public health needs must be protected. In practice, greater capacity to work within intellectual property and competition rules, and use TRIPs flexibilities4 would help improve access for Medical products.

WHO policies promote appropriate access to medical products, in line with the WHO’s global strategy and plan of action on public health, innovation and intellectual property, including policies on: access to generic medicines and innovation; quality-assurance of products through effective regulation and promoting rational use of medical products.

Access to essential medicines has been a priority in the Regional Flagship on UHC since 2014. To improve the quality and safety of medical products India is actively participating to promote regulatory collaboration for access to medical products through the South-East Asia Regulatory Network (SEARN). South-East Asia Region Member States Regional Committee has endorsed ten medicines-related resolutions since 2002, of which four are current5.

The 1st World Conference on Access to Medical Products and International Laws for Trade and Health, in the Context of the 2030 Agenda for Sustainable Development held in New Delhi, 2017 focused substantially on ways to address these challenges6. The 1st World Conference 2017 led to 142 recommendations related to national and international policies for Access to medical products agenda (in the framework of globalization and trade agreements). The contribution of partners to the Conference: WHO, Biotechnology Industry Research Assistance Council (BIRAC), a public sector undertaking of the Department of Biotechnology, Translational Health Science and Technology Institute (THSTI), an autonomous institute of the Department of Biotechnology, Ministry of Science and Technology, Government of India, ICMR, Indian Society for International Law was invaluable. Key ministry(ies) have been identified for implementation of the Recommendations and nodal officers are designated to jointly coordinate for the purpose.

2 WHA67.20: Regulatory system strengthening for medical products, WHA67.23 Health intervention and technology assessment in support of universal health coverage (UHC), WHA68.7: Global action plan on antimicrobial resistance, WHA69.11: Health in the 2030 Agenda for Sustainable Development, WHA70.7: Improving the prevention, diagnosis and clinical management of sepsis, WHA70.12: Cancer prevention and control in the context of an integrated approach, WHA71.12: Addressing the global shortage of, and access to, medicines and vaccines, WHA71.18: Global strategy and plan of action on public health, innovation and intellectual property

3 Roadmap for Access 2019-2023; http://www.who.int/medicines/access_use/road-map-medicines-vaccines/en/4 The 1994 Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) focused on patent

protection. The 2001 Doha Declaration in WTO emphasized “TRIPs flexibilities” as measures to protect public health.

5 International trade and health (SEA/RC59/R9); Measures to ensure access to safe, efficacious and affordable medical products (SEA/RC62/R6); National essential drug policy including the rational use of medicines (SEA/RC64/R5); Effective management of medicines (SEA/RC66/R7).

6 http://www.worldsdg2030.org/

66

Given the importance of the agenda, the Ministry of Health announced the “2nd World Conference on Access to Medical Products – Achieving the SDGs 2030” during the 2017 Conference itself. The 2nd World Conference 2018 seeks to build on the consensus and deliberations made in the previous Conference. The Agenda of the 2nd World Conference 2018 reflects these priorities.

Colour Scheme Session Themes

Inaugural & Closing SessionsPlenary SessionParallel Sessions

Plenary Wrap Up SessionsLunch and Tea Breaks

77

Preliminary Overview Programme

Time 9 October 2018(Tuesday) Hall

7:30-8:45 Registration8:45-10:15 Inaugural Session Plenary Hall

10:15-11:00 Tea Break11:00-12:15 Plenary Session 1

Access to Medical Products to achieve SDGs 2030 Plenary Hall

12:15-13:30 Parallel Session 1Policies to support Innovation for Medical Products (in select countries)

Plenary Hall

Parallel Session 2State Health Ministers’ Roundtable Panel on Access to Medical Products

Board Room

13:30-14:30 Lunch14:30-16:00 Parallel Session 3

Tracking Investments in Medical Products Research & Development

Plenary Hall

Parallel Session 4 Union Government Secretaries and Principal Secretaries from States Roundtable Panel-Progress of 1st World Conference on Access to Medical Products and Strengthening Regulation in States

Lecture Hall 1

16:00-16:30 Tea Break16:30-18:00 Plenary Session 2

Mechanisms for Knowledge Sharing including Licensing Options for Medical Products for Health for all

Plenary Hall

18:00-18:30 Wrap Up Plenary Session: Summary of the Plenary and Parallel Sessions Plenary Hall

19:00 Cultural Programme and Dinner Plenary Hall10 October 2018

(Wednesday)09:00-10:30 Plenary Session 3

Strengthening Regulatory Networks for Facilitating Access to Quality, Safe and Affordable Medical Products

Plenary Hall

10:30-10:45 Tea Break10:45-12:15 Plenary Session 4

Global Models for High-end Manufacturing of Medical Products

Plenary Hall

88

12:15-13:30 Parallel Session 5Standard Setting and Quality Benchmarks for Medical Devices and Diagnostics in National and Global Markets

Plenary Hall

12:15-13:30 Parallel Session 6Medical Diagnostics- Promoting Health for all Lecture Hall 1

13:30-14:30 Lunch14:30-16:00 Parallel Session 7

Promoting Health and Wellness through Traditional Medicine

Lecture Hall 1

Parallel Session 8Developing Efficiencies in Clinical Trials in Global, Regional and National Settings

Plenary Hall

Parallel Session 9Access and Affordability of Medical Products-Focus Orphan and Rare Drugs

Lecture Hall 2

16:00-16:30 Tea Break16:30-17:30 Wrap Up Plenary Session: Summary of the Plenary and

Parallel Sessions Plenary Hall

11 October 2018(Thursday)

09:00-10:30 Plenary Session 5Reengineering How We Finance Delivery and Access to Medical Products: The 3Rs of Sharing Resources, Risks and Rewards

Plenary Hall

10:30-11:00 Tea Break11:00-13:00 Plenary Session 6

Legal and Regulatory Issues for Access to Medical Products

Plenary Hall

13:00-14:00 Lunch14:00-15:30 Parallel Session 10

Partnering for Access to Medical Products-Bilateral Treaties and Regional Agreements

Plenary Hall

Parallel Session 11Non Communicable Diseases-Legal Aspects for Prevention and Promotion of Public Health

Lecture Hall 1

Parallel Session 12Intellectual Property Rights and Standards in Trade for Medical Products

Lecture Hall 2

15:30-16:30 Plenary Session 7: Closing Session, Summary and Recommendations

Plenary Hall

16:30-17:00 High Tea

99

Detailed ProgrammeTuesday 9 October 2018

9 October 2018-Tuesday, 7:30-8:45: RegistrationInaugural Session- Tuesday, 9 October 2018: 8:45-10:15

Dr RK Vats, Additional Secretary, Ministry of Health & Family Welfare, Government of IndiaDr Henk Bekedam, WHO Representative to IndiaDr Mariângela Batista Galvão Simão, Assistant Director-General for Drug Access, Vaccines and Pharmaceuticals, WHO GenevaDr Renu Swarup, Secretary, Department of Biotechnology, Ministry of Science and Technology, Government of IndiaDr Balram Bhargava, Secretary, Department of Health Research, Ministry of Health and Family Welfare, Government of IndiaMr Ajay Prakash Sawhney, Secretary, Ministry of Electronics and Information Technology, Government of IndiaMr Ramesh Abhishek, Secretary, Department Of Industrial Policy & Promotion, Ministry of Commerce and Industry, Government of IndiaDr Arun Panda, Secretary, Ministry of Micro Small and Medium Enterprises, Government of IndiaDr Poonam Khetrapal Singh, Regional Director, WHO South-East Asia RegionMs Preeti Sudan, Secretary, Health, Ministry of Health and Family Welfare, Government of IndiaDr VK Paul, Member, NITI Aayog, Government of IndiaHonorable Ms Anupriya Patel, Minister of State, Health & Family Welfare, Government of IndiaHonorable Mr Ashwini Kumar Chaubey, Minister of State, Health & Family Welfare, Government of IndiaDr Tedros Adhanom Ghebreyesus, Director General, World Health Organization (Video Address)Honorable Dr Harsh Vardhan, Union Minister, Ministry of Science and Technology, Government of IndiaRelease of “Position Paper-2nd World Conference on Access to Medical Products–Achieving the SDGs 2030”Launch of “South East Asia Regulatory Network Information Sharing Platform Gateway”Honorable Mr JP Nadda, Union Minister, Health & Family Welfare, Government of India

Group Photo9 October 2018-Tuesday, 10:15-11:00: Tea Break

1010

Tuesday 9 October 2018: ProgrammeGPW 13, Innovation, Manufacturing

9 October 2018-Tuesday, 11:00-12:15: Plenary Session 1: Access to Medical Products to achieve SDG 2030 Goals

Time Plenary Session 1- Tuesday, 09 October 2018 Room

Tuesday, 11:00-12:15

Access to Medical Products to achieve SDG 2030 Goals Chairs: Mr JP Nadda, Union Minister, Health & Family Welfare, Government of IndiaDr Harsh Vardhan, Union Minister, Ministry of Science and Technology, Government of India Special Addresses: • Dr Poonam Khetrapal Singh, Regional Director, WHO South-

East Asia Region • Ms Preeti Sudan, Secretary, Health, Ministry of Health and

Family Welfare, Government of India

Plenary Hall

Keynote Addresses 1. Dr Mariângela Batista Galvão Simão, Assistant Director-

General for Drug Access, Vaccines and Pharmaceuticals, WHO, Switzerland- Contribution of 13th GPW for Access to Medical Products to achieve SDG 2030 Goals

2. Dr Nata Menabde, Executive Director of the WHO Office at the United Nations, New York, USA- Health focus in 2019 UN General Assembly-NCDs and TB

3. Dr Indu Bhushan, Chief Executive Officer, Ayushman Bharat Programme, Government of India- Universal Health Coverage in India: Bringing Healthcare to the People through National Health Protection Scheme

1111

09 October, 2018-Tuesday, 12:15-13:30: Parallel Session 1- Policies to support Innovation for Medical Products (in select countries)

Time Parallel Session 1 - Tuesday, 9 October, 2018 Room

Tuesday, 12:15-13:30

Policies to support Innovation for Medical Products (in select countries)Chair: Dr Poonam Malakondaiah, Special Chief Secretary, Health, Medical and Family Welfare, Government of Andhra Pradesh, IndiaCo-chair: Dr Henk Bekedam, WHO Representative to India

Plenary Hall

Key Note Addresses: • Dr Mariângela Batista Galvão Simão, Assistant

Director-General for Drug Access, Vaccines and Pharmaceuticals, WHO, Switzerland- Policy Options Promoting Innovation in Health Technologies- Select MERCOSUR Countries

• Dr S Leigh Verbois, Assistant Commissioner for International Programs, US FDA, USA- Facilitating Access: The Role of Innovation and Competition

• Dr Jitendar Sharma, CEO, Andhra MedTech Zone, and Advisor, Kalam Institute of Health Technology, India– Policy Initiatives to Promote Medical Devices and Diagnostics

Panelists1. Dr Calvin Ho, Assistant Professor, Centre for Biomedical

Ethics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore- Mainstreaming Medical Ethics in Delivery for Fostering Quality and Safety of Health Services

2. Dr Alka Sharma, Advisor, Department of Biotechnology, Ministry of Science and Technology, Government of India- Department of Biotechnology’s Supporting Role in the Innovations Ecosystem in India

3. Dr Anil Koul, Director, CSIR-Institute of Microbial Technology, India-Towards Unipill for TB treatment

4. Dr Pavan Asalapuram, CEO, EMPE Diagnostics, Sweden- Developing Rapid Diagnostic Solutions for Infectious Diseases: Focus on antibiotic resistance and Tuberculosis Tuberculosis & Sexually Transmitted Infections

1212

09 October, 2018-Tuesday, 12:15-13:30: Parallel Session 2- State Health Ministers’ Roundtable Panel on Access to Medical Products

Time Parallel Session 2 - Tuesday, 9 October, 2018 Room

Tuesday, 12:15-13:30

State Health Ministers’ Roundtable Panel on Access to Medical Products Chair: Mr JP Nadda, Union Minister, Health & Family Welfare, Government of IndiaCo-Chair: Mr Ashwini Kumar Chaubey, Minister of State, Health & Family Welfare, Government of IndiaModerated By: Dr Nata Menabde, Executive Director of the WHO Office at the United Nations, New York, USA

Board Room

Key Note Addresses:• Dr Balram Bhargava, Secretary, Department of Health

Research, Ministry of Science and Technology, and Director General, Indian Council for Medical Research, Government of India

• Dr Poonam Khetrapal Singh, Regional Director, WHO South-East Asia Region

State Health Ministers’ InterventionsDetails to be circulated in Conference

09 October, 2018-Tuesday, 13:30-14:30: Lunch

1313

09 October, 2018-Tuesday, 14:30-16:00: Parallel Session 3: Tracking Investments in Medical Products Research & Development

Time Parallel Session 3- Tuesday, 09 October, 2018 Room

Tuesday, 14:30-16:00

Tracking Investments in Medical Products Research & Development Chair: Dr Mariângela Batista Galvão Simão, Assistant Director-General for Drug Access, Vaccines and Pharmaceuticals, WHO, SwitzerlandCo-chairs: Mr PN Ranjit Kumar, Joint Secretary, Ministry of AYUSH, Government of India

Plenary Hall

Key Note Address• Dr Mark Rohrbaugh, Special Adviser-Tech Transfer,

National Institutes of Health, USA- The Role of NIH in Development of New Drugs & Vaccines

• Mr Robert Terry, Manager-Research Policy, The Special Programme for Research and Training in Tropical Diseases, World Health Organization, Switzerland-Funding Global Health Product R&D and the Portfolio-To-Impact Model

Panelists1. Mr Niclas Jacobson, Deputy Director-General, Ministry

of Health and Social Affairs, Sweden- Improving information in policy making for access to Medical Products

2. Dr Vipul Chowdhary, Analyst, Policy Cures Research, Australia- Facilitating policy through tracking investments in product R&D

3. Dr Suman Rijal, Executive Director, Drugs for Neglected Diseases (DNDi), India- Drug development project portfolio: DNDi Experience

4. Dr Shirshendu Mukherjee, Mission Director, Biotechnology Industry Research Assistance Council, India- Grand Challenges Indian Contribution in Promoting Research & Development

1414

09 October, 2018-Tuesday, 14:30-16:00: Parallel Session 4: Union Government Secretaries and Principal Secretaries from States Roundtable Panel-Progress of 1st World Conference on Access to Medical Products and Strengthening Regulation in States

Time Parallel Session 4- Tuesday, 09 October, 2018 Room

Tuesday, 14:30-16:00

Union Government Secretaries and Principal Secretaries from States Roundtable Panel-Progress of 1st World Conference on Access to Medical Products and Strengthening Regulation in States Chair: Ms Preeti Sudan, Secretary, Health, Ministry of Health and Family Welfare, Government of IndiaCo-chair: Dr Nata Menabde, Executive Director of the WHO Office at the United Nations, New York, USA

Lecture Hall 1

1. Dr Renu Swarup, Secretary, Department of Biotechnology, Ministry of Science and Technology, Government of India

2. Dr Balram Bhargava, Secretary, Department of Health Research, Ministry of Science and Technology, and Director General, Indian Council for Medical Research, Government of India

3. Mr Ramesh Abhishek, Secretary, Department of Industrial Policy and Promotion, Ministry of Commerce and Industry, Government of India

4. Mr Vaidya Rajesh Kotecha, Secretary, Ministry of AYUSH, Government of India

5. Mr Suresh Chandra, Secretary, Ministry of Law and Justice, Government of India

6. Dr Poonam Malakondaiah, Special Chief Secretary, Health, Government of Andhra Pradesh

7. Dr J Radha Krishnan, Principal Secretary, Health, Government of Tamil Nadu

8. Mr V Vumlunmang, Principal Secretary (Health & FW) Department of Health & Family Welfare, Government of Manipur

9. Mr Rajeev Sadanandan, Additional Chief Secretary (Health), Department of Health & Family Welfare, Government of Kerala

10. Mr Satish Chandra, Additional Chief Secretary (Health & FW), Department of Health & Family Welfare, Government of Punjab

11. Mr Vivek Pandey, Secretary (Health), UT of Lakshadweep12. Mr Ajay Seth, Additional Chief Secretary (H&FW), Health

and FW Department, Government of Karnataka

09 October, 2018-Tuesday, 16:00-16:30: Tea Break

1515

09 October 2018-Tuesday, 16:30-18:00: Plenary Session 2: Mechanisms for Knowledge Sharing including Licensing Options for Medical Products to Facilitate Health for all

Time Plenary Session 2- Tuesday, 9 October 2018 Room

Tuesday, 16:30-18:00

Mechanisms for Knowledge Sharing including Licensing Options for Medical Products for Health for all Chair and Opening Remarks: Justice Prathibha M Singh, Judge, Delhi High Court, IndiaCo-chair: Mr Arun Singhal, Additional Secretary, Ministry of Health & Family Welfare, Government of India

Plenary Hall

Key Note Address:• Dr Mark Rohrbaugh, Special Advisor-Technology Transfer,

National Institute of Health, USA- Intellectual Property Protection and Licensing under the Bayh-Dole Act

Panelists1. Mr Alok Kumar, Adviser, NITI Aayog, Government of

India- Accelerated Inclusive Innovation Led Growth- Making Technology Work For Everyone

2. Dr Christer Backman, Senior Expert, International Relations, Medical Products Agency, Sweden- National and International Incentives to Promote Market Authorization on Pediatric Medical Products

3. Dr Kavita Singh, Mission Director, Biotechnology Industry Research Assistance Council, India- Enabling Regulatory Ecosystem for Innovation in Health Technologies

4. Dr KS Kardam, Senior Joint Controller Patents and Designs, Indian Patent Office, India- IPR and Public Health: Indian Patent Office Practice

5. Mr Guilherme Cintra, Senior Manager-IP &Trade, International Federation of Pharmaceutical Manufacturers & Association, Sweden- New Licensing Approaches For Access To Medical Products

1616

09 October 2018-Tuesday, 18:00-18:30: Wrap Up Plenary Session: Summary of the Plenary and Parallel Sessions

TimeWrap Up Plenary Session: Summary of the Plenary and Parallel Sessions- Tuesday, 09

October 2018

Room

Tuesday, 18:00-18:30

Chair: Ms Preeti Sudan, Secretary, Health, Ministry of Health and Family Welfare, Government of India Co-chair: Dr RK Vats, Additional Secretary, Ministry of Health and Family Welfare, Government of India; Mr Sudhir Kumar, Joint Secretary, Ministry of Health and Family Welfare, Government of India;Dr Eswara Reddy, Drugs Controller General of India, Central Drug Standard Control Organization, India

Plenary Hall

Plenary Session 1: Access to Medical Products to achieve SDG 2030 GoalsPresentation by RapporteurPlenary Session 2: Mechanisms for Knowledge Sharing including Licensing Options for Medical Products to Facilitate Health for allPresentation by RapporteurParallel Sessions 1: Policies to support Innovation for Medical Products (in select countries)Presentation by RapporteurParallel Sessions 3: Tracking Investments in Medical Products Research & DevelopmentPresentation by Rapporteur

09 October 2018-Tuesday, 19:00hrs-Cultural Programme- Plenary Hall and Dinner-Restaurant

1717

Wednesday, 10 October 2018:ProgrammeRegulation & Access

10 October 2018- Wednesday, 08:00-09:00: Registration

10 October 2018- Wednesday, 09:00-10:30: Plenary Session 3: Strengthening Regulatory Networks for Facilitating Access to Quality, Safe and Affordable Medical Products

Time Plenary Session 3- Wednesday, 10 October 2018 Room

Wednesday, 9:00-10:30

Strengthening Regulatory Networks for Facilitating Access to Quality, Safe and Affordable Medical Products Chairs: Dr Renu Swarup, Secretary, Department of Biotechnology, Ministry of Science and Technology, Government of India;Mr Ajay Prakash Sawhney, Secretary, Ministry of Electronics and Information Technology, Government of IndiaCo-chairs: Dr RK Vats, Additional Secretary, Ministry of Health and Family Welfare, Government of India;Dr Mariângela Batista Galvão Simão, Assistant Director-General for Drug Access, Vaccines and Pharmaceuticals, WHO, Switzerland

Plenary Hall

Panelists1. Dr Eswara Reddy, Drugs Controller General of India,

Central Drug Standard Control Organization, India- Strengthening Regulatory Systems for Medical Products in India and for Global Markets including SEARO

2. Dr S Leigh Verbois, Assistant Commissioner for International Programs, US FDA, USA- Strengthening the Supply Chain

3. Dr Manisha Shridhar, Regional Advisor, WHO South-East Asia Regional Office, India- Access to Medical Products: Impact of Regulation, Trade, and Intellectual Property-Opportunities for Collaboration

4. Mr Rishi Prakash, Joint Director, e-Governance; Ms Payal Saluja, Principal Technical Office, Centre for Development of Advanced Computing, India- Leveraging Information Sharing Platform for SEARN Countries

10 October 2018- Wednesday, 10:30-10:45: Tea Break

1818

10 October, 2018-Wednesday, 10:45-12:15: Plenary Session 4: Global Models for High-end Manufacturing of Medical Products

Time Plenary Session 4- Wednesday, 10 October, 2018 Room

Wednesday, 10:45-12:15

Global Models for High-end Manufacturing of Medical ProductsChairs: Dr Renu Swarup, Secretary, Department of Biotechnology, Ministry of Science and Technology, Government of India;Dr Balram Bhargava, Secretary, Department of Health Research, Ministry of Science and Technology, and Director General, Indian Council for Medical Research, Government of IndiaDr Indu Bhushan, Chief Executive Officer, Ayushman Bharat Programme, Government of India Moderated By: Mr Lav Agarwal, Joint Secretary, Ministry of Health & Family Welfare, Government of India

Plenary Hall

Keynote Addresses:• Dr Renu Swarup, Secretary, Department of

Biotechnology, Ministry of Science and Technology, Government of India- Ideation to Commercialization of Medical Products-DBT Initiatives

• Dr Balram Bhargava, Secretary, Department of Health Research, Ministry of Science and Technology, and Director General, Indian Council for Medical Research, Government of India- High Tech Manufacturing for Local Healthcare Needs- Providing Adaptive Technology Solutions

Panelists1. Dr Poonam Malakondaiah, Special Chief Secretary,

Health, Medical and Family Welfare, Government of Andhra Pradesh, India- India’s Boost to Global Manufacturing for High Tech Medical Devices and Diagnostics

2. Dr Manisha Shridhar, Regional Advisor, WHO South-East Asia Regional Office, India; Dr Madhur Gupta, Technical Officer-Pharmaceuticals, WHO India- Fostering Local Production and Technology Transfer for Medical Products

3. Dr Arun Bhardwaj, Director, Central Drugs Laboratory-Kasauli, India-Quality Manufacturing to Meet National and Global Vaccine Needs

4. Dr Rajiv Nath, Association of Indian Medical Device Industry, India- Accelerating Innovation (Faster Up-Gradation of Existing Technology and Global New Product Innovation)

1919

10 October 2018- Wednesday, 12:15-13:30: Parallel Session 5: Standard Setting and Quality Benchmarks for Medical Devices and Diagnostics in National and Global Markets

Time Parallel Session 5– Wednesday 10 October 2018Room

Wednesday,12:15-13:30

Standard Setting and Quality Benchmarks for Medical Devices and Diagnostics in National and Global Markets Chairs: Dr Renu Swarup, Secretary, Department of Biotechnology, Ministry of Science and Technology, Government of India;Ms Surina Rajan, Director General, Bureau of Indian Standards, Government of IndiaCo-Chair: Mr Sudhansh Pant, Joint Secretary, Ministry of Health and Family Welfare, Government of India

Plenary Hall

Key Note Addresses: • Dr VG Somani, Joint Drugs Controller India,

Central Drug Standard Control Organization, India- Regulatory Landscape Reforms for Medical Devices and Diagnostics in India

• Dr RK Bajaj, Deputy Director General; Bureau of Indian Standards, Government of India; Dr Prakash Bachani, Head Medical Equipment Planning, Bureau of Indian Standards, Government of India- Promoting Quality through Standards in Medical Products

Panelists 1. Dr Jitendar Sharma, CEO, Andhra MedTech

Zone, and Advisor, Kalam Institute of Health Technology, India- Developing Ecosystem for Quality Diagnostics and Devices

2. Dr Reba Chhabra, Deputy Director-Quality Control Diagnostics & HOO, National Institute of Biologicals, India- Critical Support by Labs for Quality Diagnostics

2020

10 October 2018- Wednesday, 12:15-13:30: Parallel Session 6: Medical Diagnostics- Promoting Health For All

Time Parallel Session 6- Wednesday, 10 October, 2018 Room

Wednesday, 12:15-13:30

Medical Diagnostics- Promoting Health For All Chair: Dr Balram Bhargava, Secretary, Department of Health Research, Ministry of Science and Technology, and Director General, Indian Council for Medical Research, Government of India Co-chair: Mr Manoj Jhalani, Additional Secretary, Ministry of Health and Family Welfare, Government of India

Lecture Hall 1

Panelists1. Dr Ravi Kant Sharma, Deputy Drugs Controller, Central

Drug Standard Control Organization, India- Regulatory Updates for Medical Devices and Diagnostics in India

2. Dr Madhur Gupta, Technical Officer-Pharmaceuticals, WHO India- WHO India Support for National Initiative on EDL

3. Dr Kamini Walia, Scientist E, Indian Council of Medical Research, India- Development of First Ever National Diagnostics List: The Indian experience

4. Dr Zachary Katz, Chief Access Officer, FIND-Introduction of New Point Of Care Diagnostics for HIV, Malaria and TB

5. Dr SB Sinha, Advisor Healthcare Technology, National Health Systems Resource Centre, India- Free Diagnostics (and Biomedical Equipment Maintenance) for Universal Health Coverage in India

10 October 2018- Wednesday, 13:30-14:30: Lunch

2121

10 October 2018- Wednesday, 14:30-16:00: Parallel Session 7: Promoting Health and Wellness through Traditional Medicine

Time Parallel Session 7- Wednesday, 10 October 2018 Room

Wednesday, 14:30-16:00

Promoting Health and Wellness Through Traditional Medicine Chair: Mr Vaidya Rajesh Kotecha, Secretary, Ministry of AYUSH, Government of IndiaCo-chair: Mr Sudhir Kumar, Joint Secretary, Ministry of Health and Family Welfare, Government of India

Lecture Hall 1

Panelists1. Dr DC Katoch, Adviser, Ministry of AYUSH, Government

of India- Integrating Traditional Medicine With Modern System Of Medicine For Achieving Public Health Goals

2. Dr Ishwar V Basavaraddi, Director, Morarji Desai National Institute of Yoga, Ministry of AYUSH, Government of India- The Role Of Traditional Medicine Practice In Prevention Of Non-Communicable Diseases

3. Dr Vijay Laxmi Asthana, Senior Scientist, CSIR-National Institute of Science Communication and Information Resources, India-Traditional Knowledge Digital Library (TKDL)

4. Dr KS Dhiman, Director General, Central Council For Research In Ayurvedic Sciences, Ministry of AYUSH, Government of India- Strengthening The Evidence Base Of Medical Products Through Research In Ayurvedic Medicine Systems

5. Dr Asim Ali Khan, Director General, Central Council for Research in Unani Medicine, Ministry of AYUSH, Government of India- Integration Of Traditional Medicines Into The Health Systems: The Unani Council Experience

6. Dr Kim Sungchol, Regional Adviser- Traditional Medicine, WHO South-East Asia Regional Office, India- WHO South East Asia Regional Perspective on Traditional Medicine

7. Dr Jing Xu, Deputy Director, National Administration of Traditional Chinese Medicine, China- Ensuring Quality and Standards In Traditional Medicines In China

2222

10 October 2018- Wednesday, 14:30-16:00: Parallel Session 8: Developing Efficiencies in Clinical Trials in Global, Regional and National Settings

Time Parallel Session 8- Wednesday, 10 October 2018 Room

Wednesday, 14:30-16:00

Developing Efficiencies in Clinical Trials in Global, Regional and National Settings Chair: Dr VK Paul, Member, NITI Aayog, Government of IndiaCo-chair: Dr BD Athani, Former Director General Health Services; Principal Consultant, Ministry of Health and Family Welfare, Government of India Moderater: Dr Eswara Reddy, Drugs Controller General Of India, Central Drug Standard Control Organization (CDSCO), India

Plenary Hall

Key Note Addresses-Best Practices in Clinical Trials• Dr Balram Bhargava, Secretary, Department of Health

Research, Ministry of Science and Technology, and Director General, Indian Council for Medical Research, Government of India

• Dr Preetha Rajaraman, India Health Attaché, US Department of Health, US Embassy

Panelists 1. Dr P Paul Kumaran, Scientist E, National Institute for

Research in Tuberculosis, India- Ethical and Regulatory considerations in Clinical Trials in India

2. Lt Gen Velu Nair, Group Technical Head, Cluster of Comprehensive Blood and Cancer Centres, USA & Former DG-Medical Services (Army), India- Accreditation of Ethics Committees in the Context of Clinical Trials: The India Experience

3. Dr M Vishnu Vardhana Rao, Scientist G & Director, NIMS, Indian Council for Medical Research, India- Disclosure of Clinical Trials Results by Stakeholders: Clinical Trial Registry of India Experience

4. Dr Sunder Raman, Head-Global Regulatory Affairs, Biocon, India- Strategies to Accelerate Access to High Quality Biosimilars for Global Patients

2323

10 October 2018- Wednesday, 14:30-16:00: Parallel Session 9: Access and Affordability of Medical Products-Focus Orphan and Rare Drugs

Time Parallel Session 9- Wednesday, 10 October 2018 Room

Wednesday, 14:30-16:00

Access and Affordability of Medical Products-focus Orphan and Rare drugs Chairs: Mr Sudhanshu Pandey, Additional Secretary- Trade Policy Division, Ministry of Commerce and Industry, Government of India;Dr Mariângela Batista Galvão Simão, Assistant Director-General for Drug Access, Vaccines and Pharmaceuticals, WHO, Switzerland Co-chairs: Mr Navdeep Rinwa, Joint Secretary, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India;Dr Chandershekhar, Additional Director General, Indian Council for Medical Research, India

Lecture Hall 2

Panelists 1. Dr S Leigh Verbois, Assistant Commissioner for International

Programs, US FDA, USA- FDA Role in Facilitating Access of Medical Products for Orphan and Rare Diseases

2. Dr Yannis Natsis, Policy Manager, Universal Access and Affordable Medicines, European Public Health Alliance, Belgium- European Public Health Alliance Contribution for Universal Access and Affordable Medicines

3. Dr Calvin Ho, Assistant Professor, Centre for Biomedical Ethics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore- Timely Access to Innovative Drugs but with Affordable Prices

4. Dr Inthira Yamabhai, IHPP, Ministry of Public Health, Thailand- Pricing Policy and Local Manufacturing for Affordable Medicines

5. Mr James Love, Director, Knowledge Ecology International, USA- Orphan Drugs Tax Credits and Cost of Clinical Trials

6. Dr Anuj Sharma, National Professional Officer-AMR & Labs, WHO India- Development of Indian Priority Pathogen List (IPPL) of Antibiotic-Resistant Bacteria to Guide Research, Discovery and Development of New Antibiotics

10 October 2018- Wednesday, 16:00-16:30: Tea Break

2424

10 October 2018- Wednesday, 16:30-17:30: Wrap Up Plenary Session: Summary of the Plenary and Parallel Sessions

TimeWrap Up Plenary Session: Summary of the

Plenary and Parallel Sessions-Wednesday, 10 October 2018

Room

Wednesday, 16:30-17:30

Chairs: Dr Balram Bhargava, Secretary, Department of Health Research, Ministry of Science and Technology, and Director General, Indian Council for Medical Research, Government of India; Dr RK Vats, Additional Secretary, Ministry of Health and Family Welfare, Government of IndiaCo-chair: Mr Sudhir Kumar, Joint Secretary, Ministry of Health and Family Welfare, Government of India

Plenary Hall

Plenary Session 3: Strengthening Regulatory Networks for Facilitating Access to Quality, Safe and Affordable Medical ProductsPresentation by RapporteurPlenary Session 4: Global Models for High-end Manufacturing of Medical ProductsPresentation by RapporteurParallel Session 5: Standard Setting and Quality Benchmarks for Medical Devices and Diagnostics in National and Global MarketsPresentation by RapporteurParallel Session 6: Medical Diagnostics- Promoting Health For AllPresentation by RapporteurParallel Session 7: Promoting Health and Wellness through Traditional Medicine Presentation by RapporteurParallel Sessions 8: Developing Efficiencies in Clinical Trials in Global, Regional and National SettingsPresentation by RapporteurParallel Sessions 9: Access and Affordability of Medical Products–focus Orphan and Rare drugsPresentation by Rapporteur

2525

Thursday 11 October 2018: ProgrammeFinancing, Legal Landscape & Trade-related Aspects 11 October 2018-Thursday, 08:00-09:00: Registration

11 October 2018-Thursday, 09:00-10:30: Plenary Session 5: Reengineering How We Finance Delivery and Access to Medical Products: The 3Rs of Sharing Resources, Risks and Rewards

Time Plenary Session 5- Thursday, 11 October 2018 Room

Thursday, 9:00-10:30

Reengineering How We Finance Delivery and Access to Medical Products: The 3Rs of Sharing Resources, Risks and Rewards Chair: Justice Prathibha M Singh, Judge, Delhi Court, IndiaCo-chairs: Dr K Vijay Raghavan, Principal Scientific Adviser to the Government of India;Dr Anthony D So, Professor of the Practice and Director, IDEA (Innovation + Design Enabling Access) Initiative, Department of International Health, Johns Hopkins Bloomberg School of Public Health, USA

Plenary Hall

Keynote Address: Dr Anthony D So, Professor of the Practice and Director, IDEA (Innovation + Design Enabling Access) Initiative, Department of International Health, Johns Hopkins Bloomberg School of Public Health, USA- Reengineering How We Finance Delivery and Access to Medical Products: The 3Rs of Sharing Resources, Risks and RewardsPanelists1. Ms Rachael Crockett, Policy Adviser, Global Policy

Team, Wellcome Trust, UK- Approach To Equitable Access To Healthcare Interventions

2. Dr Manica Balasegaram, Director, GARDP, DNDi, Switzerland- Role of Product Development Partnerships for Access to Health Technologies

3. Dr Johan Lennart Struwe, Public Health Agency of Sweden, Sweden- Rational Use of Antibiotics Implemented though the Swedish Strategic Programme for Antibiotic Resistance

4. Dr Kavitha Rajsekar, Scientist, Department of Health Research, Ministry of Health and Welfare, Government of India- Bringing Better Healthcare To People In India-Role Of Health Technology Assessment

11 October 2018-Thursday, 10:30-11:00: Tea Break

2626

11 October 2018-Thursday, 11:00-13:00: Plenary Session 6: Legal and Regulatory Issues for Access to Medical Products

Time Plenary Session 6- Thursday, 11 October 2018 Room

Thursday, 11:00-13:00

Legal and Regulatory Issues for Access to Medical Products Chair: Mr Suresh Chandra, Secretary, Ministry of Law and Justice, Government of IndiaCo-Chair: Mr Shyamal Misra, Joint Secretary, Department of Commerce, Ministry of Commerce and Industry, Government of India

Plenary Hall

Key Note Addresses:• Dr Anthony D So, Professor of the Practice and

Director, IDEA (Innovation + Design Enabling Access) Initiative, Department of International Health, Johns Hopkins Bloomberg School of Public Health, USA- Designing Innovative Approaches to Improving Antimicrobial Stewardship through Drug Regulation

Panelists1. Dr Manica Balasegaram, Director, GARDP, DNDi,

Switzerland- New Global Initiatives for Innovation of Medical Products- Global Antibiotic R&D Partnership (GARD-P)

2. Dr Olasupo Owoeye, Senior Lecturer, Law, RMIT Graduate School of Business and Law, Australia- Intellectual Property, Access to Medicines and Universal Health Coverage Through a Health Rights Lens

3. Dr K Bangarurajan, Joint Drugs Controller India, Central Drug Standard Control Organization, Government of India- Regulatory Updates to Foster an Enabling Landscape for Access to Medical Products

4. Mr DG Shah, Indian Pharmaceutical Alliance, India- Innovation and IPR in Indian Pharmaceutical Industry

5. Dr Gayatri Saberwal, Scientist and Dean, Institute of Bioinformatics and Applied Biotechnology, India- Bio-incubation Clusters and Initiatives in India for Health Technologies

6. Ms Stefanie Freel, Access to Medicines Foundation, Netherlands- Access & Stewardship: How do Companies Address the Affordability of Antibiotics

11 October 2018-Thursday, 13:00-14:00: Lunch

2727

11 October 2018-Thursday, 14:00-15:30: Parallel Session 10: Partnering for Access to Medical Products-Bilateral treaties and Regional Agreements

Time Parallel Session 10- Thursday, 11 October 2018 Room

Thursday, 14:00-15:30

Partnering for Access to Medical Products-Bilateral Treaties and Regional Agreements Chairs: Mr Rajiv Aggarwal, Joint Secretary, Department of Industrial Policy and Promotion, Ministry of Commerce and Industry, Government of IndiaMr GR Raghavender, Joint Secretary, National Mission for Justice Delivery and Legal Reforms, Ministry of Law and Justice, Government of India

Plenary Hall

Panelists1. Dr Mohga Kamal Yanni, Senior Health and HIV

Policy Adviser, Oxfam GB, UK- Developing systems and approaches for Access to Medical products in Free Trade Agreements

2. Dr Cha-aim Pachanee, International Health Policy Program, Ministry of Public Health, Thailand- Thailand’s Engagement for Public Health in Bilateral and Regional Agreements

3. Mr DG Shah, Indian Pharmaceutical Alliance, India- Partnering for Access to Medical Products in Bilateral Treaties and Regional Agreements

4. Dr Sachin Chaturvedi, Director General, Research & Information System for Developing Countries, India- Achieving the Sustainable Development Goals (SDGs): Strengthening Regional Cooperation and Resources for the SDGs

5. Mr KM Gopakumar, Legal Advisor, Third World Network, India- Progress on TRIPS Flexibilities since Doha Declaration since 2001

6. Ms Catherina Timmermans, Technical Manager, Intellectual Property, UNITAID, Switzerland- Overcoming Patent Barriers: Options and Impact

2828

11 October 2018-Thursday, 14:00-15:30: Parallel Session 11: Non Communicable Diseases-Legal Aspects for Prevention and Promotion of Public Health

Time Parallel Session 11- Thursday, 11 October 2018 Room

Thursday, 14:00-15:30

Non Communicable Diseases-Legal Aspects for Prevention and Promotion of Public Health Chair: Dr Arun Panda, Secretary, Ministry of Micro Small and Medium Enterprises, Government of India; Dr Suresh Chandra, Secretary, Ministry of Law and Justice, Government of IndiaCo-chair: Mr Vikas Sheel, Joint Secretary, Ministry of Health and Family Welfare, Government of India

Lecture Hall 1

Panelists1. Dr Padmini Angela De Silva, Regional Adviser-

Nutrition, WHO South-East Asia Regional Office, India- Nutrition and NCDs

2. Dr Christer Backman, Senior Expert, International Relations, Medical Products Agency, Sweden- Regulations, Standards and Licensing of Medical Products

3. Ms Sunita K Sreedharan, Lawyer, SKS Law Associates, India-Legal Regulations Preventing Non-Communicable Diseases Governance with Special Reference to India

4. Dr Biswajit Dhar, Professor, Jawaharlal Nehru University, India- Research Institutions Licensing Practices For Prioritizing Public Health

5. Mr Rajesh Murthy, Business Development Manager-Head of Indian Operations, Medicines Patent Pool, India- Innovative Licensing Mechanisms: The Medicines Patent Pool Perspective

2929

11 October 2018-Thursday, 14:00-15:30: Parallel Session 12: Intellectual Property Rights and Standards in Trade for Medical Products

Time Parallel Session 12- Thursday, 11 October 2018 Room

Thursday, 14:00-15:30

Intellectual Property Rights and Standards in Trade for Medical Products Chair: Mr Sudhanshu Pandey, Additional Secretary- Trade Policy Division, Ministry of Commerce and Industry, Government of IndiaCo-chairs: Dr S Eswara Reddy, Drugs Controller General Of India, Central Drug Standard Control Organization, Government of India

Lecture Hall 2

Panelists1. Dr Olasupo Owoeye, Senior Lecturer, Law, RMIT Graduate

School of Business and Law, Australia- New Initiatives in PDPs for Access to Affordable Medical Products

2. Dr Purnima Sharma, Managing Director, Biotech Consortium India Limited, India- Bringing First Generation Entrepreneurs to the Market Place For Medical Devices

3. Dr H Purshottam, Chairman and Managing Director, National Research Development Corporation, India- Health Technology Transfer

4. Ms Leena Menghaney, Head-South Asia, Access Campaign, Medecins Sans Frontieres, India- Patents as a Tool for Innovation- Challenges in the NCD Medical Products Pipeline

5. Mr Avirup Bose, Associate Professor and Assistant Director, Centre for International Trade and Economics Laws, Jindal Global Law School, India-The Legal Landscape in Competition Law and Access to Medical Products

6. Dr Yashwant D Panwar, Scientist E, Patent Facilitating Centre, India- Inventions to Improve Healthcare

7. Dr Ujjwal Kumar, Policy Analyst, CUTS International, India- Interface of IPR and Competition Law

3030

11 October 2018-Thursday, 15:30-16:30: Plenary Session 7: Closing Session, Summary and Recommendations

Closing session- Thursday, 11 October 2018: 15:30-16:30

Dr RK Vats, Additional Secretary, Ministry of Health & Family Welfare, Government of India

Dr Renu Swarup, Secretary, Department of Biotechnology, Ministry of Science and Technology, Government of India

Dr Balram Bhargava, Secretary, Department of Health Research, Ministry of Health and Family Welfare, Government of India

Dr K Vijay Raghavan, Principal Scientific Adviser to the Government of India

Dr VK Paul, Member, NITI Aayog, Government of India

Dr Poonam Khetrapal Singh, Regional Director, WHO South-East Asia Region

Ms Preeti Sudan, Secretary, Health, Ministry of Health and Family Welfare, Government of India

Dr Soumya Swaminathan, Deputy Director General, WHO, Switzerland [Video Address]

Honorable Mr JP Nadda, Union Minister, Health & Family Welfare, Government of India

11 October 2018- Thursday, 16:30-17:00: High Tea

3131

Conference Website http://www.worldsdg2030.org

Declaration of Interest Some of the participants will be given a declaration of interest format, which needs to be duly completed, signed and returned to the Registration Desk.

Disclaimer © World Health Organization 2018

The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions accepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Registration and Name TagsWhen arriving to the venue, each participant needs to register at the counter and sign to get the Name Tag from the registration desk. During the conference, you need to wear your badge at all times to be allowed inside of the Forum space.

Mobile AppA Mobile App for the conference has been developed to facilitate background resource material in an easy to read mode on an android/smart phone, for ease of accessing documents. It is also envisaged you will find the mobile app useful in intra-venue navigation here in the hotel, from other hotels to this hotel. Certain features are available to enable taking down points and views which may not be possible to cover through discussion and question and answer sessions. Thus, Suggestions for Outcomes, chat with conference secretariat etc. have been made possible.

Once the participant is registered for the conference on the Website, a link for Mobile-app will be sent to the registered email-ID to download the App in your phone (both Android/i-OS). Once logged –in the App will function in offline mode also.

Visa LetterOnce the participant is registered for the conference on the Website, an automated e-visa letter can be generated in a downloadable format. The letter can then be used to obtain Visa from the consulate.

Invitation LetterOnce the participant is registered for the conference on the Website, an automated e-invitation letter can be generated in a downloadable format.

3232

Useful Information

Venue Pravasi Bhartiya Kendra15A, 15B and 15D, Dr.Rizal Marg, Chanakyapuri, New Delhi, Delhi 110021

Local Transport With a vision to provide a safe, clean, comfortable, efficient, cost-effective yet sophisticated, and personalized public transport system, radio taxis were introduced in Delhi to improve the commuting experience. If you would like to Rent a Cab or Hire a Cab in Delhi, you can easily avail professional, comfortable, air-conditioned Radio taxi services from various Radio Cab companies.

Radio Taxis are available for local commuting as well as long distance purposes. Hiring a cab in Delhi allow you to get the cab number and driver’s mobile number as well.

All cabs are equipped with following features:• Air conditioned luxury cabs.• Round-the-clock availability (24x7), there are no problems of timing and safety.• Backed by GPS technology to track location.• Digital cab meters integrated with the GPRS technology and thermal printers for

issuing bill/receipt etc. The billing is done on a per kilometer basis from point to point.

• In - Car payment facility; customer can pay through cash or credit card (check credit card facility with the cab driver) as well.

A few leading radio taxi operatorsTaxi Operator Phone Number Web Address

Easy Cab +91-11-43434343 www.easycabs.comMega Cab +91-11-41414141 http://www.megacabs.com/delhi.phpMeru Cab +91-11-44224422 www.merucabs.com

Chanson Cab +91-11-47774777 http://caratcall.com/tariff.phpYo Cab +91-11-44664466 http://yocabs.com/Air Cab +91-11-48484848 http://aircab.co.in/HomeStyle1.aspx

Quick Cab +91-11- 67676767 +91-11-45333333

http://quickcabs.in/

Ola Cab https://www.olacabs.com/car-rentals/delhi

Also, you can download the mobile phone apps in your cell phones for any of the taxi services provided above and book cabs online.

3333

Each hotel at Delhi has the facility to arrange for cabs; you can ask the hotel reception for arranging the cab 15-30 minutes prior.

FoodThe Lunch and Tea Breaks are complimentary by the secretariat from 09-11 October 2018. The Reception Dinner on 09 October 2018 would be hosted by the secretariat for all the participants at the venue i.e. Pravasi Bhartiya Kendra.

CurrencyThe Rupee is the official currency of India. The Indian Rupee may be abbreviated in any of the following formats INR, Rs, or ` symbol

INR are available as paper notes in denominations of 5, 10, 50, 100, 200, 500 and 2000. INR are also available as coins in denominations of 1, 2, 5 and 10.

Local TimeIndian Standard Time (IST) is 5 hours 30 minutes ahead of GMT.

Weather in OctoberThroughout the month of October day-time temperatures will generally reach highs of around 33°C. At night the average minimum temperature drops down to around 21°C. The average daily relative humidity for October is around 52%

3434

Delhi in BriefLocated in Northern India, Delhi is said to be one of the oldest cities in the world. With 22 million inhabitants, it is India’s capital and a hub of the country’s politics, culture and commercial activity. It is one of the world’s leading cities, with eminence in the arts, commerce, education, entertainment, fashion, healthcare, professional services, research and development and tourism all contributing to its prominence. Delhi, located on the bank of the Yamuna River, is a microcosm of India.

The city is known for its historical monuments. It became the capital of a Muslim empire in India under Qutubuddin Aibak, builder of the Qutub Minar, in 1193. Sir Edwin Landseer Lutyens planned New Delhi and designed the majestic Rashtrapati Bhawan (President House, formerly the palace of the Viceroy) as well as the parliament and other important government buildings. The architecture of these buildings is mainly European, with details of indigenous Indian styles. The weather in Delhi in November is expected to be between a max of 29.6°C and minimum of 11.5 °C. Delhi is easily reachable from all major countries of the World and to domestic travellers from anywhere in India. Being one of the most historic Capitals in the world, Delhi has a plethora of tourist sites.

Experience the culture and heritage that Delhi has to offer by visiting the landmarks of Delhi.

Located in Northern India, Delhi is said to be one of the oldest cities in the world. With 22 million inhabitants, it is India’s capital and a hub of the country’s politics, culture and commercial activity.

Delhi is easily reachable from all major countries of the World and to domestic travellers from anywhere in India.

There are many options that one can avail from to reach Delhi.

You can reach Delhi by:Air: Indira Gandhi International Airport is the eight largest airport in the world. The airport is the major domestic air hub of the region and is also connected to all the major cities of the world. More information from http://www.newdelhiairport.in

Rail: Delhi is the headquarters of the Northern Railway and is a very well connected railhead with all major cities and towns in India. The main railway stations are New Delhi, Delhi Junction (Old Delhi), Hazrat Nizamuddin and Sarai Rohilla.

Road: Delhi is connected by good motorable roads to all major places in India.

Annexures

3737

1 Honorable Mr JP Nadda, Union Minister, Health & Family Welfare,Ministry of Health and Family Welfare,Government of Indiahfm@gov.in

2 Honorable Dr Harsh Vardhan, Union Minister, Ministry of Science and Technology, Government of Indiadrharshvardhan@sansad.nic.in

3 Honorable Mr Ashwini Kumar Chaubey, Minister of State, Health & Family Welfare,Ministry of Health and Family Welfare, Government of Indiaav.gawai@nic.in

4 Honorable Ms Anupriya Patel, Minister of State, Health & Family Welfare, Ministry of Health and Family Welfare, Government of Indiaofficeanupriyapatel@gmail.com

5 Mr Satyendar Jain Minister of Health Government of NCT of Delhi moh.delhi@gov.in

6 Mr Vipin Singh ParmarMinister of Health & Family Welfare, Revenue & Law Government of Himachal Pradesh vipinparmar@gmail.com

7 Mr Malladi Krishna RaoMinister of Health & Family Welfare Government of Puducherry tourism.pon@nic.in

Annex IList of Participants

Ministers

8 Mr Brahm MohindraMinister of Health & Family Welfare Government of Punjabdycmoffice@punjab.gov.inbrahm_mohindra@yahoo.com

9 Dr C Vijaya BaskarMinister of Health & Family Welfare, Medical Education Government of Tamil Nadu hfsec@tn.gov.inrasibluemeta109@ymail.com

10 Mr Siddharth Nath SinghMinister of Medical & HealthGovernment of Uttar Pradesh snsbjp@gmail.com

11 Mr Farooq Khan,IPS Administrator Union Territory of Lakshadweep lk-admin@nic.in

Senior Officials from Ministries, Chairs and Co-Chairs

12 Dr VK Paul, Member, NITI Aayog, Government of IndiaVinodk.paul@gov.in

13 Justice Pratibha Singh, Judge, Delhi High Court, Indiapratibha@pmsingh.in

14 Dr K Vijay Raghavan, Principal Scientific Adviser to the Government of Indiavijay@ncbs.res.in

15 Ms Preeti Sudan, Secretary, Health, Ministry of Health and Family Welfare, Government of Indiasecyhfw@nic.in

3838

16 Dr Poonam Khetrapal Singh, Regional Director, WHO South-East Asia Regionsinghpoonam@who.int

17 Ms Vijaya Srivastava, Special Secretary & Financial Adviser, Ministry of Health & Family Welfare, Government of Indiavijaya.srivastava@nic.in

18 Dr Renu Swarup, Secretary, Department of Biotechnology, Ministry of Science and Technology, Government of Indiasecy.dbt@nic.in

19 Dr Balram Bhargava, Secretary, Department of Health Research,Ministry of Health and Family Welfare, Government of IndiaBalram.bhargava@gov.in

20 Mr Ajay Prakash Sawhney, Secretary, Ministry of Electronics and Information Technology, Government of Indiasecretary@meity.gov.in

21 Mr Ramesh Abhishek, Secretary, Department Of Industrial Policy & Promotion, Ministry of Commerce and Industry, Government of IndiaSecy-ipp@nic.in

22 Dr Arun Panda, Secretary, Ministry of Micro Small and Medium Enterprises, Government of IndiaSecretary-msme@nic.in

23 Ms Surina Rajan, Director General, Bureau of Indian Standards, Government of Indiadg@bis.gov.in

24 Mr Vaidya Rajesh Kotecha, Secretary, Ministry of AYUSH,Government of IndiaSecy-ayush@nic.in

25 Mr Suresh Chandra, Secretary, Ministry of Law and Justice, Government of Indiasureshchandra@nic.in

26 Dr RK Vats, Additional Secretary,Ministry of Health & Family Welfare, Government of Indiaasdgcghs-mohfw@nic.in

27 Mr Manoj Jhalani, Additional Secretary, Ministry of Health and Family Welfare, Government of India manoj.jhalani@nic.in

28 Mr Sudhanshu Pandey, Additional Secretary- Trade Policy Division, Ministry of Commerce and Industry, Government of IndiaJs1tpd@nic.in

29 Mr Sanjeeva KumarAdditional Secretary, Minister, Health & Family Welfare, Government of Indiaash-mohfw@nic.in

30 Mr Arun Singhal, Additional Secretary, Ministry of Health & Family Welfare, Government of Indiaarun.singhal@nic.in

3939

31 Dr Indu Bhushan, Chief Executive Officer, Ayushman Bharat Programme, Government of Indiai.bhushan@gov.in

32 Dr Nata Menabde, Executive Director of the WHO Office at the United Nations, New York, USAmenabden@who.int

33 Dr Mariângela Batista Galvão Simão, Assistant Director-General for Drug Access, Vaccines and Pharmaceuticals, WHO, Switzerlandsmaom@who.int

34 Dr Henk Bekedam, WHO Representative to IndiaOffice of the WHO Representative to Indiabekedamh@who.int

35 Mr Rajiv Aggarwal, Joint Secretary, Department of Industrial Policy and Promotion, Ministry of Commerce and Industry, Government of IndiaRajiv.aggarwal@nic.in

36 Mr Sudhir Kumar, Joint Secretary, Ministry of Health and Family Welfare, Government of IndiaKumar14@nic.in

37 Mr Navdeep Rinwa, Joint Secretary,Janpath BhawanDepartment of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of IndiaJs.pharma@nic.in

38 Mr Sudhansh Pant, Joint Secretary,Ministry of Health and Family Welfare, Government of IndiaJs.me-mohfw@nic.in

39 Mr Lav Agarwal, Joint Secretary, Ministry of Health & Family Welfare, Government of Indiaalav@ias.nic.in

40 Mr PN Ranjit Kumar, Joint Secretary, Ministry of AYUSH, Government of IndiaJspnrk-ayush@gov.in

41 Mr GR Raghavender,Joint Secretary, National Mission for Justice Delivery and Legal Reforms, Ministry of Law and Justice, Government of Indiaraghavender.gr@nic.in

42 Mr Vikas Sheel, Joint Secretary, Ministry of Health and Family Welfare, Government of Indiasheelv@nic.in

43 Mr Shyamal Misra, Joint Secretary, Department of Commerce, Ministry of Commerce and Industry, Government of Indiamisra.shyamal@gov.in

44 M V VumlunmangPrincipal Secretary (Health & Family Welfare)Department of Health & Family Welfare,Government of Manipurmang@nic.in

4040

45 Ms Poonam MalakondaiahSpecial Chief Secretary Health Medical & Family Welfare Department & Mission Director (NHM) Government of Andhra Pradeshprl.secy.hmfwap@gmail.com

46 Mr Rajeev SadanandanAdditional Chief Secretary (Health) Department of Health & Family Welfare, Government of KeralaSecy.hlth@kerala.gov.in

47 Mr Satish ChandraAdditional Chief Secretary (Health & Family Welfare),Department of Health & Family Welfare, Government of Punjabpstca14@gmail.com

48 Dr J Radha Krishnan Principal Secretary (Health & Family Welfare),Department of Health & Family Welfare, Government of Tamilnaduhfwsec@gmail.com

49 Mr Vivek PandeySecretary (Health),UT of Lakshadweep, lk-advisor@gov.in

50 Mr Ajay Seth, Additional Chief Secretary (H&FW),Health and FW Department,Government of Karnatakaajayseth@nic.in

51 Mr Prashant TrivediPrincipal Secretary,Department of Health & Family Welfare, Government of Uttar Pradesh,psecup.health@gmail.com

52 Dr Anthony D So, Professor-Practice & Director, IDEA (Innovation + Design Enabling Access) Initiative,Department of International Health, Johns Hopkins Bloomberg School of Public Health, USA aso5@jhu.edu

53 Dr S Eswara Reddy, Drugs Controller General Of India, Central Drug Standard Control Organization, Government of Indiadci@nic.in

54 Dr Chander Shekhar,Additional Director General, Indian Council for Medical Research, IndiaShekharc57@yahoo.com

55 Dr BD Athani, Former Director General Health Services; Principal Consultant, Ministry of Health and Family Welfare, Government of Indiabd.athani56@nic.in

International Participants and Officials

56 Dr Preetha RajaramanHHS Health AttachU.S. Department of Health & Human ServicesU.S. Embassy, Shantipath, ChanakyapuriNew Delhi- 110021rajaramanp@state.gov

57 Mr Niclas Jacobson, Deputy Director-General, Ministry of Health and Social Affairs, Sweden niclas.jacobson@gov.se

4141

58 Dr Vipul Chowdhary, Analyst, Policy Cures Research, Australia VChowdhary@policycuresresearch.org

59 Dr S Leigh Verbois, Assistant Commissioner for International Programs, US FDA, USALeigh.Verbois@fda.hhs.gov

60 Dr Calvin Ho, Assistant Professor, Centre for Biomedical Ethics, Yong Loo Lin School of Medicine, National University of Singapore, Singaporemedhwlc@nus.edu.sg

61 Dr Pavan AsalapuamCEOEMPE Diagnostics ABSwedenpavan@empediagnostics.com

62 Ms Stefanie FreelAccess to Medicines Foundation, Netherlandssfreel@accesstomedicinefoundation.org

63 Dr Christer Backman, International Coordinator, International Relations, Swedish Medical Products AgencySwedenChrister.backman@mpa.se

64 Robert Terry Manager-Research PolicyTDR-World Health PolicySwitzerlandterryr@who.int

65 Dr Mark Rohrbaugh, Special Adviser-Tech Transfer, National Institutes of Health, USAmark.rohrbaugh@nih.gov

66 Dr Zachary Katz, Chief Access Officer, FINDzachary.katz@finddx.org

67 Dr Yannis Natsis, Policy Manager, Universal Access and Affordable Medicines, European Public Health Alliance, Belgiumyannis.natsis@gmail.com

68 Dr Inthira Yamabhai, IHPP, Ministry of Public Health,Thailandinthira@ihpp.thaigov.net

69 Mr James Love, Director, Knowledge Ecology International, USAjames.love@keionline.org

70 Ms Rachael Crockett, Policy Adviser, Global Policy Team, Wellcome Trust, UKR.Crockett@wellcome.ac.uk

71 Dr Manica Balasegaram, Director, GARDP, DNDi, Switzerlandmbalasegaram@dndi.org

72 Dr Johan Lennart Struwe, Public Health Agency of Sweden, Swedenjohan.struwe@folkhalsomyndigheten.se

73 Mr Guilherme Cintra, Senior Manager-IP &Trade, International Federation of Pharmaceutical Manufacturers & Association, SwedenG.Cintra@ifpma.org

4242

74 Dr Jing XuDeputy DirectorNational Administration of Traditional Chinese MedicinelIndiaxujing@satem.gov.cn

75 Dr Olasupo Owoeye, Senior Lecturer, Law, RMIT Graduate School of Business and Law, Australiaolasupo.owoeye@rmit.edu.au

76 Dr Mohga Kamal Yanni, Senior Health and HIV Policy Adviser, Oxfam GB, UKmkamalyanni@oxfam.org.uk

77 Dr Cha-aim Pachanee, ResearcherInternational Health Policy Program, Ministry of Public Health,Thailandchaaim@ihpp.thaigov.net

78 Ms Catherina Timmermans, Technical Manager-Intellectual Property, UNITAID, Switzerlandtimmermansc@who.int

79 Ms Elizabeth Diana DewiPolicy AnalystMinistry of Foreign Affairs of the Republic of IndonesiaIndonesiaelizabethdewi80@gmail.com

80 Ms Anna SahlströmHead of International AffairsSwedenanna.sahlstrom@sll.se

81 Lars Magnus AhlanderBusiness managerAleris Diagnostic AB, SwedenLars.ahlander@aleris.se

82 Ms Anne SnyderGlobal Health OfficerU.S. Department of Health and Human Services, USAanne.snyder@hhs.gov

83 Mr Gabriel AndreassonHead of SectionMinistry of Health and Social Affairs of Sweden, Swedengabriel.andreasson@gov.se

84 Ms Yasmin Zaveri RoySenior AdvisorEmbassy of Sweden, Indiayasmin.zaveri-roy@gov.se

85 Ms Vanessa VossFirst Secretary,Australian High CommissionVanessa.voss@dfat.gov.au

86 Dr Himangi BhardwajSenior Health AdviserBritish High Commissionhimangi.bhardwaj@fco.gov.uk

87 Mr Vidya Nag NukalaSenior AdvisorBiomedical Science & TechnologyU.S. Department of Health & Human ServicesU.S. Embassy, IndiaNukalaVN@state.gov

88 Ms Widya FitriPolicy AnalystMinistry of Foreign Affairs of the Republic of Indonesia, Indonesiawidya.fitri@kemlu.go.id

89 Dr Bizoza AimablePharmacistBurundiaimablebizoza@gmail.com

90 Mr Barayandema RaphaelGMP InspectorMoH/DPMLBujumburarbarayandema@yahoo.fr

4343

91 Mr Pelden ChejorSenior Regulatory OfficerDrug Regulatory AuthorityBhutanpchejor@dra.gov.bt

92 Mr Dawa TsheringRegulatory OfficerDrug Regulatory AuthorityBhutandtshering@dra.gov.bt

93 Dr Jan Akko EleveldProgramme ManagerUNITAID, Switzerlandeleveldj@who.int

94 Mr Lars AhlanderBusiness ManagerAleris Diagnostics ABSwedenLars.ahlander@aleris.se

95 Ms Chinta AbayawardanaPast President (Pharmaceutical Society), Sri Lankachintaab@gmail.com

96 Ms Shampa Saira BariProject ManagerSwedenshampa.bari@swecare.se

97 Mr Elder UcheCEO87 Micheal Jackson Crescent Gwarinpa, Abujaibuzoch@gmail.com

98 Ms Tabitha Charlotte HaAdvocacy and Campaigns Officer - Access to Medicin, OXFAMOxfam House, John Smith DriveOxford, Oxfordshire- OX4 2JYtabitha.ha@oxfam.org

99 Dr Kofi TurksonMedical PractitionerMinistry of healthp.o.box ks 10735, Kumasi ashbentsi2011@gmail.com

100 Mr David SumoManaging DirectorLMHRA, MONROVIA, NON-USAd.sumo@yahoo.com

101 Mr Nagarajah RajkumarDeputy Project DirectorMinistry of Planning and Economic Affairs, Sri Lankarajacqueline@yahoo.com

102 Ms Iris ÖhrnInvestment Advisor- HealthcareBusiness Region Swedeniris.ohrn@businessregion.se

103 Mr Shekhar NatarajanHead of International Regulatory StrategyShire PharmaceuticalsUnited Kingdomshnatarajan@shire.com

104 Ms Emily Elizabeth BleimundU.S. Department of Health & Human Services, USAEmily.Bleimund@hhs.gov

105 Ms Ann Elizabeth DanelskiU.S. Department of Health & Human ServicesUSAann.danelski@hhs.gov

106 Mr Ryoba Marwa Mangera Assistant Lecturer University of Dodoma, Tanzania ryoba12@gmail.com

107 Mr Dusan Jasovsky AMR/Regulatory Pharmacist Doctors Without Borders/Access Campaign, Switzerland dusan.jasovsky@geneva.msf.org

108 Mrs Maria HellingCEO Swecare Foundation Sweden maria.helling@swecare.se

4444

109 Prof Philippe Guerin Professor University of Oxford Centre for tropical medicine & global health, Oxford United Kingdom philippe.guerin@iddo.org

National Participants and Officials

110 Dr Jitendar Sharma, CEO, Andhra MedTech Zone, and Advisor, Kalam Institute of Health Technology, Indiaceo@amtz.in

111 Dr S VenkateshDirector General of Health ServicesDirectorate General Of Health ServicesMinistry of Health & Family WelfareGovernment of Indiadghs@nic.in

112 Dr Alka Sharma, Advisor, Department of Biotechnology, Ministry of Science and Technology, Government of IndiaAlka.dbt@nic.in

113 Dr Anil Koul, Director, CSIR-Institute of Microbial Technology, Indiadirector@imtech.res.in

114 Dr Rajiv Nath, Association of Indian Medical Device Industry, Indiaforumcoordinator@aimedindia.com

115 Dr Kavita Singh, Mission Director,Biotechnology Industry Research Assistance Council, Indiatechnical.birac@gov.in

116 Dr Suman Rijal, Executive Director, Drugs for Neglected Diseases (DNDi), Indiasrijal@dndi.org

117 Dr Shirshendu Mukherjee, Mission Director, Biotechnology Industry Research Assistance Council, Indiamdpmubmgf.birac@nic.in

118 Mr Alok Kumar, Adviser, NITI Aayog, Government of Indiaalokkumar.up@ias.nic.in

119 Dr KS Kardam, Senior Joint Controller Patents and Designs, Indian Patent Office, IndiaKardam.ks@nic.in

120 Dr Arun Bhardwaj, Director, Central Drugs Laboratory-Kasauli, Indiaarun_kasauli@yahoo.co.in

121 Mr Rishi Prakash, Joint Director, e-GovernanceCentre for Development of Advanced Computingpvrishi@cdac.in

122 Ms Payal Saluja, Principal Technical Office, Centre for Development of Advanced Computing, Indiapayals@cdac.in

123 Dr S. Eswara Reddy, Drugs Controller General of India, Central Drug Standard Control Organization, Indiadci@nic.in

4545

124 Dr RK BajajScientist G & DDG(Standardization)Bureau of Indian Standardsdrbajaj@gmail.com

125 Dr Prakash Bachani, Head Medical Equipment Planning, Bureau of Indian Standards, Government of Indiahmhd@bis.gov.in

126 Dr Reba Chhabra, Deputy Director-Quality Control Diagnostics & HOO, National Institute of Biologics, Indiarchhabra@nib.gov.in

127 Dr Kamini Walia, Scientist E, Indian Council of Medical Research, Indiawaliakamini@gmail.com

128 Dr SB Sinha, Advisor Healthcare Technology, National Health Systems Resource Centre, IndiaShashiBhushan.Sinha@nhsrcindia.org

129 Dr DC Katoch, Adviser, Ministry of AYUSH, Government of Indiadc.katoch@gov.in

130 Dr KS Dhiman, Director General, Central Council For Research In Ayurvedic Sciences, Indiadg-ccras@nic.in

131 Dr Asim Ali Khan, Director General, Central Council for Research in Unani Medicine , Indiaasim.ccrum@gmail.com

132 Dr Kim Sungchol, Regional Adviser- Traditional Medicine, WHO South-East Asia Regional Officekims@who.int

133 Dr Vijay Laxmi Asthana, Senior Scientist, CSIR-National Institute of Science Communication and Information Resources, Indiaviji@csir.res.in

134 Dr P Paul Kumaran, Scientist E, National Institute for Research in Tuberculosis, Indiappaulkumaran@nirt.res.in

135 Lt Gen Velu Nair, Group Technical Head, Cluster of Comprehensive Blood and Cancer Centres, USA & Former DG-Medical Services (Army), Indiadrvelunair@cbccusa.in

136 Dr VG Somani, Joint Drugs Controller India, Central Drug Standard Control Organization, Indiav.g.somani30@cdsco.nic.in

137 Dr Ravi Kant Sharma, Deputy Drugs Controller, Central Drug Standard Control Organization, Indiaadcrks@gmail.com

138 Dr M Vishnu Vardhana Rao, Scientist G & Director, NIMS, Indian Council for Medical Research, Indiadr_vishnurao@yahoo.com

139 Dr Sunder Raman, Head-Global Regulatory Affairs,Biocon, Indiasundar.ramanan@biocon.com

4646

140 Dr Anuj Sharma, National Professional Officer-AMR & Labs, WHO Indiasharmaan@who.int

141 Mr DG Shah, Indian Pharmaceutical Alliance, Indiadgshah@vision-india.com

142 Dr Gayatri Saberwal, Scientist and Dean, Institute of Bioinformatics and Applied Biotechnology, Indiagayatri@ibab.ac.in

143 Dr Sachin Chaturvedi, Director General, Research & Information System for Developing Countries, Indiasachin@ris.org.in

144 Mr KM GopakumarLegal AdvisorThird world Network (TWN)Indiakmgkumar@gmail.com

145 Ms Sunita K Sreedharan, Lawyer, SKS Law Associates, Indiasunita@skslaw.org

146 Dr Padmini Angela De Silva, Regional Adviser-Nutrition, WHO South-East Asia Regional Officedesilvap@who.int

147 Dr Biswajit Dhar, Professor, Jawaharlal Nehru University, Indiabiswajit@mail.jnu.ac.in

148 Dr H Purshottam, Chairman and Managing Director, National Research Development Corporation, Indiacmdnrdc@nrdc.in

149 Ms Leena Menghaney, Head-South Asia-Access Campaign, Medecins Sans Frontieres, Indialeena.menghaney@msf.org

150 Avirup Bose, Associate Professor and Assistant Director, Centre for International Trade and Economics Laws, Jindal Global Law School, Indiaabose@jgu.edu.in

151 Dr Yashawant D Panwar, Scientist E, Patent Facilitating Centre,Indiayashawant@tifac.org.in

152 Mr Ujjwal KumarPolicy AnalystCUTS Internationalujk@cuts.org

153 Dr Kavitha Rajsekar, Scientist, Department of Health Research,Ministry of Health and Welfare,Government of IndiaKavitha.rajsekar@nic.in

154 Dr K Bangarurajan, Joint Drugs Controller India, Central Drug Standard Control Organization, Government of Indiabangaru@cdsco.nic.in

155 Mr Rajesh Murthy, Business Development Manager-Head of Indian Operations,Medicines Patent Pool, Indiarmurthy@medicinespatentpool.org

156 Dr Rimy Khurana Research Assistant Health Division, NITI Aayogrimy.khurana@nic.in

4747

157 Dr Sonali RawalConsultant Health Division,NITI Aayograwal.sonali@nic.in

158 Dr Deepika RohatgiScientist ‘D’Department of Scientific & Industrial Research,Ministry of Science & Technology,deepika.roh@nic.in

159 Dr Nitin Kumar JainScientist EDepartment of BiotechnologyMinistry of Science & Technology,nitink.jain@nic.in

160 Ashok Kumar MadanExecutive DirectorIndian Drug Manufacturers Association, Indiaakmadan.idma@gmail.com

161 Dr Sarabjit ChadhaRegional Technical DirectorFIND, IndiaSarabjit.Chadha@finddx.org

162 Ms. Ranu BhogalDirector Policy Research and CampaignsOxfam Indiaranu@oxfamindia.org

163 Mr Devarshi BhattacharyyaAssistant DirectorKalam Institute of Health TechnologyAMTZ Campus, Indiab.devarshi@kiht.in

164 Ms Shamaila KhalilProgramme Coordinator- HealthOxfam Indiashamaila@oxfamindia.org

165 Ms Jyotsna SinghAdvocacy OfficerMSF, Indiajyotsna.singh@geneva.msf.org

166 Ms Seema P RathAssociate ProfessorGovernment College of Arts, Science and Commerce, SanquelimPG Dept. of Economics, Govt. College, Goa, Indiaseemapr@yahoo.com

167 Ms Ebba SjoedahlInternEmbassy of SwedenIndiaebba.sjodahl@gov.se

168 Mr Lal Sawma PachuauJoint Director (Food & Drugs)Health & Family Welfare DepartmentMizorammizoramfda2@gmail.com

169 Ms Mousumi MondalSenior Manager PartnershipIndiammmondal@dndi.org

170 Ms Guljit Sethi DirectorBioinnovat, Indiaguljit@bioinnovat.com

171 Shweta BhardwajManager- Government Affairs, Indiashweta.bharwaj@medtronic.com

172 Alagu Subramaniam ARManaging DirectorWest Pharma, Indiaalagu.subramanian@westpharma.com

4848

173 Ms. Jyotsna GhosalSenior Director –Corporate AffairsMerck Phama.IndiaJyotsna_ghosal@merck.com

174 Veer kumar MotaManaging DirectorSkylark medical India Pvt. Ltd.Indiaveeruaero53@gmail.com

175 Gaurav Mendiratta Director- Medical devices, Pharma & IPRAMCHAM India gaurav@amchamindia.com

176 Dr Parvesh YadavAssistant Medical SuperintendentNational Institute of Tuberculosis and Respiratory DiseasesIndiap.yadav@nitrd.nic.in

177 Dr Sanjay GuptaCMO (SAG)National Institute of Tuberculosis and Respiratory DiseasesIndias.gupta@nitrd.nic.in

178 Dr Vikram VohraCMO(SAG)National Institute of Tuberculosis and Respiratory Diseases, Indiav.vohra@nitrd.nic.in

179 Dr Puneet AroraIncharge- Procurement Cell.National Institute of Tuberculosis and Respiratory Diseases,Indiap.arora@nitrd.nic.in

180 Dr Banusri VelpandianConsultantBiotechnology Industry Research Assistance Counci, Indiabanusriv@gmail.com

181 Mr Anil ChauhanSenior AdviserAssociation of Biotechnology Led Enterprises, Indiaanil@ableindia.org.in

182 Mr Vibhav GargVice President-Health Policy & Government AffairsGE Healthcare, Indiavibhav.garg@ge.com

183 Mr Chirag JasaniSenior Assistant DirectorFICCI, Indiachirag.jasani@ficci.com

184 Mr Praveen Kumar MittalDirectorFICCIFederation House, Tansen MargNew Delhi- 110001praveen.mittal@ficci.com

185 Ms Swati AggarwalConsultantFICCIFederation House, Tansen MargNew Delhi- 110001swati.aggarwal@ficci.com

186 Mr. Kamal BhardwajJoint DirectorFICCI, Indiakamal.bhardwaj@ficci.com

187 Dr Rakesh Sharma Professor- Pediatrics,Indra Gandhi Medical CollegeShimla, Indiadrrakeshigmc@gmail.com

188 Mr Mayank RohatgiDirector- Lifesciences,Manufacturing and Supply Chain LogisticsU.S. India Bussiness Council, Indiamrohtgi@usibc.com

4949

189 Mr Nayanima BasuDirector- Strategy and CommunicationsU.S. India Bussiness CouncilIndianbasu@usibc.com

190 Mr Sushil Kumar SahuTechnical Officer Central Drugs LaboratoryKasauli, Indiacdlkasauli@cdsco.nic.in

191 Dr Vivek BansalTechnical SupervisorCentral Drugs LaboratoryKasauli, Indiacdlkasauli@cdsco.nic.in

192 Mr Devender BarthwalTechnical SupervisorCentral Drugs LaboratoryKasauli, Indiacdlkasauli@cdsco.nic.in

193 Dr Promila Gupta Principal ConsultantDirectorate General of HealthServicesMinistry of Health and Family Welfare, Government of Indiagupta.promila@nic.in

194 Dr AK GadpayleAdditional Director GeneralDirectorate General of Health ServicesMinistry of Health and Family Welfare, Government of Indiaaddldg_dg@gov.in

195 Dr Anil ManaktalaDeputy Director General(P)Directorate General of Health ServicesMinistry of Health and Family Welfare, Government of Indiaanil.manak@nic.in

196 Dr Manju BalaDeputy Director General(M) Directorate General of Health ServicesMinistry of Health and Family Welfare, Government of Indiaddgm@nic.in

197 Dr Bina R Sawhney Additional Deputy Director General, Directorate General of Health ServicesMinistry of Health and Family Welfare, Government of Indiabina.sawhney@nic.in

198 Dr SK Kushwaha Additional Deputy Director General,Directorate General of Health ServicesMinistry of Health and Family Welfare, Government of Indiasks.kushwaha.cghs@nic.in

199 Dr Tanu JainAdditional Deputy GeneralDirectorate General of Health ServicesMinistry of Health and Family Welfare, Government of Indiatanu.jain69@nic.in

200 Dr Indu GrewalCMO- NFSGDirectorate General of Health ServicesMinistry of Health and Family Welfare, Government of Indiadrindugrewal@gmail.com

201 Mr PBN PrasadDeputy Drugs Controller(I)CDSCO(WZ) MumbaiCentral Drug Standard Control Organization, Government of India pulijala_bnprasad@yahoo.com

5050

202 Dr Rubina BoseDeputy Drugs Controller(I)Central Drug Standard Control Organization (WZ) Mumbai, Government of Indiarubina.bose@cdsco.nic.in

203 Dr A RamkrishanDeputy Drugs Controller(I)Central Drug Standard Control Organization (EZ) Mumbai, Government of Indiaramkrishnan.n@nic.in

204 Ms Shanthy Gunasekaran Deputy Drugs Controller(I) Central Drug Standard Control Organization (SZ) Chennai, Government of Indiaszbengaluru@cdsco.nic.in

205 Ms Annam Visala Deputy Drugs ControllerHyderabad ZoneCentral Drug Standard Control Organization, Government of Indiavisala.annam@nic.in

206 Mr Arvind KukretyDeputy Drugs Controller(I)Ahmedabad ZoneCentral Drug Standard Control Organization, Government of Indiaarvindkukrety@cdsco.nic.in

207 Mr Aseem SahuDeputy Drugs Controller(I)CDSCO(NZ) Central Drug Standard Control Organization, Government of Indiaaseem.sahu@cdsco.nic.in

208 Mr AK Pradhan Deputy Drugs Controller(I) Central Drug Standard Control Organization, Government of Indiapradhanak@cdsco.nic.in

209 Mr Ranga Chandrashekhar Deputy Drugs Controller(I)Central Drug Standard Control Organization, Government of Indiaranga.cs@cdsco.nic.in

210 Ms Swati Srivastava Deputy Drugs Controller(I)Central Drug Standard Control Organization, Government of Indiaswati.s@cdsco.nic.in

211 Dr Naresh SharmaDeputy Drugs ControllerCentral Drug Standard Control Organization, Government of Indianaresh@cdsco.nic.in

212 Mr Dhananjay K. Sable Assistant Drugs Controller(I) Central Drug Standard Control Organization, Government of Indiadidksable@gmail.com

213 Mr Arvind R. HiwaleAssistant Drugs Controller(I)Central Drug Standard Control Organization, Government of Indiaarvindhiwalecdsco@gmail.com

214 Mr Suresh Kumar Kalwaniya Drugs InspectorCentral Drug Standard Control Organization, Government of Indiacdscodi.skk@gmail.com

5151

215 Mr Sidharth Sahai MalhotraDrugs InspectorCentral Drug Standard Control Organization, Government of Indiasidharth@cdsco.nic.in

216 Mr Ashish Kumar RaiDrugs InspectorCentral Drug Standard Control Organization, Government of IndiaAshishrai.cdsco@gmail.com

217 Mr S John GerardDrugs InspectorCentral Drug Standard Control Organization, Government of Indiajohncdsco@gmail.com

218 Mr Sanjay Kumar Agrawal Drugs InspectorCentral Drug Standard Control Organization, Government of Indiacdscodi@gmail.com

219 Mr NK JayasenthilDrugs InspectorCentral Drug Standard Control Organization, Government of Indiasenthil.nk@cdsco.nic.in

220 Mr Dinesh Kumar Drugs Inspector Central Drug Standard Control Organization, Government of Indiadinesh1581@gmail.com

221 Dr Anshu BhardwajSenior Scientist CSIR- Institute of Microbial tech.Assistant Professor- AcSIRIndiaanshu@imtech.res.in

222 Mr Narender Kumar Ahooja State Drugs Controller Food and Drug AdministrationHaryana, Indiasdc.fda-hry@gov.in haryanafda@gmail.com

223 Mr Adarsh Kumar Goyal Drugs InspectorFood and Drug AdministrationHaryana, Indiaharyanafda@gmail.com

224 Mr Tajber SinghState Drugs ControllerDepartment of Medical Health & Family WelfareUttrakhand, IndiaDrugcontroluk@gmail.com

225 Ms Ritu SahayDirector(Drugs) Department of Medical Health & Family WelfareJharkhand, IndiaDirectoratedrug.jharkhand@gmail.com

226 Dr Jaseela Majeed Assistant ProfessorDelhi Institute of Pharmaceutical Sciences and researchJaseelapharma2017@gmail.com

227 Devistone SwerAssistant Drug ControllerRed Hill Road,Lai